Showing 111-115 of 146 news & articles:
OM1 Giant Cell Arteritis Registry Reaches More Than 5,000 Patients Prospectively Followed With Deep Clinical Data

BOSTON, Dec. 8, 2020 /PRNewswire/ — OM1, a leading real-world, data, outcomes and technology company with a focus on chronic diseases, today announced the expansion of its Giant Cell Arteritis (GCA) registry. GCA, also known as temporal arteritis, is a chronic inflammatory artery disease that causes head pain, joint pain, vision problems, and fever. GCA affects approximately 230,000 Americans,[…]

RWD For Evaluating Device & Diagnostic Performance & Outcomes

October 12, 2020 – MedTech by Richard Gliklich, MD, CEO of OM1 and Michelle Leavy, MPH, Head of Health Policy at OM1 Read the full article Interest in real-world data (RWD) and real-world evidence (RWE) has increased rapidly since the passage of the 21st Century Cures Act in late 2016. Use of RWD and RWE for[…]

Beyond Harmonization: Implementing Standardized Outcome Measures to Support Value-Based Care

October 21, 2020- ISPOR In a recent blog post from ISPOR, Richard Gliklich, CEO of OM1 and Michelle Leavy, MPH, Head of Health Policy at OM1 detail how Implementing Standardized Outcome Measures Supports Value-Based Care. Value-based care has received significant attention in recent years as an approach to improving patient outcomes while controlling healthcare costs.[…]

New Edition Of The AHRQ Registries User’s Guide Released

BOSTON, Sept. 21, 2020 /PRNewswire/ — An update of “Registries for Evaluating Patient Outcomes: A User’s Guide: 4th Edition,” was released today, the fourth edition of a reference handbook from the U.S. Agency for Healthcare Research and Quality (AHRQ) that contains practical information on the design, operation, and analysis of patient registries. First published in 2007, the User’s Guide[…]

How can AI and RWD work together to improve understanding of chronic diseases? Q&A with Kathryn Starzyk, Head of RWE at OM1

August 13, 2020- Aetion In a recent interview, Kathryn Starzyk, epidemiologist and Head of Real-World Evidence (RWE) at OM1, shared what makes OM1’s data unique, and how she and her team partner with biopharma and health systems to generate RWE that helps researchers better understand patient journeys in disease areas including rheumatology and immunology. Read on[…]

1 … 21 22 23 24 25 … 30